Antibody αPEP13h reacts with lymphangioleiomyomatosis cells in lung nodules

Chest

Volumn 147, Issue 3, 2015, Pages 771-777

  Valencia, Julio C ^a   Steagall, Wendy K ^a   Zhang, Yi ^a   Fetsch, Patricia ^b   Abati, Andrea ^b   Tsukada, Katsuya ^a   Billings, Eric ^a   Hearing, Vincent J ^b   Yu, Zu Xi ^a   Pacheco Rodriguez, Gustavo ^a   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA PEP13H ANTIBODY; CYTOPLASM PROTEIN; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY HMB 45; PEPTIDE ANTIBODY; PROTEIN PMEL17; PROTEIN VARIANT; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; HMB-45 PROTEIN, HUMAN; MELANOCYTE PROTEIN PMEL 17;

ADULT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL ORGANELLE; CELLS BY BODY ANATOMY; CLINICAL ARTICLE; EPITHELIOID CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LUNG NODULE; LYMPHANGIOLEIOMYOMATOSIS; MELANOSOME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE; SENSITIVITY ANALYSIS; SPINDLE CELL; WESTERN BLOTTING; BIOPSY; BRONCHOSCOPY; CELL CULTURE; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; LUNG; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; SENSITIVITY AND SPECIFICITY; SOLITARY PULMONARY NODULE;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; BIOPSY; BRONCHOSCOPY; CELLS, CULTURED; DIAGNOSIS, DIFFERENTIAL; FEMALE; GP100 MELANOMA ANTIGEN; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MELANOMA-SPECIFIC ANTIGENS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SOLITARY PULMONARY NODULE;

EID: 84924871376     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-0380     Document Type: Article

References (43)

1. Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J. The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis. Lymphat Res Biol. 2010;8(1):9-19.
2. Ryu JH, Moss J, Beck GJ, et al NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173(1):105-111.
3. Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest. 2009;135(5):1293-1300.
4. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000;97(11):6085-6090.
5. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006;355(13):1345-1356.
6. Astrinidis A, Khare L, Carsillo T, et al. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet. 2000;37 (1): 55-57.
7. Badri KR, Gao L, Hyjek E, et al. Exonic mutations of TSC2/TSC1 are common but not seen in all sporadic pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2013;187(6):663-665.
8. Lesma E, Sirchia SM, Ancona S, et al. The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells. Am J Pathol. 2009;174(6):2150-2159.
9. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008;412(2):179-190.
10. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol. 2003;5(6):578-581.
11. Goncharova EA, Goncharov DA, Eszterhas A, et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem. 2002;277(34):30958-30967.
12. McCormack FX, Inoue Y, Moss J, et al National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595-1606.
13. Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med. 2011;154(12):797-805.
14. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140-151.
15. Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomy omatosis. N Engl J Med. 2008;358(2):200-203.
16. Bonetti F, Chiodera PL, Pea M, et al. Transbronchial biopsy in lymphangiomyomatosis of the lung. HMB45 for diagnosis. Am J Surg Pathol. 1993;17(11):1092-1102.
17. Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol. 1999;21(3):327-336.
18. Johnson SR, Cordier JF, Lazor R, et al Review Panel of the ERS LAM Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35(1):14-26.
19. Ferrans VJ, Yu ZX, Nelson WK, et al. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch. 2000;67(5):311-329.
20. Kobayashi T, Urabe K, Orlow SJ, et al. The Pmel 17/silver locus protein. Characterization and investigation of its melanogenic function. J Biol Chem. 1994;269(46):29198-29205.
21. Yasumoto K, Watabe H, Valencia JC, et al. Epitope mapping of the melanosomal matrix protein gp100 (PMEL17): rapid processing in the endoplasmic reticulum and glycosylation in the early Golgi compartment. J Biol Chem. 2004;279(27):28330-28338.
22. Hoashi T, Muller J, Vieira WD, et al. The repeat domain of the melanosomal matrix protein PMEL17/GP100 is required for the formation of organellar fibers. J Biol Chem. 2006;281(30):21198-21208.
23. Adema GJ, de Boer AJ, Vogel AM, Loenen WA, Figdor CG. Molecular characterization of the melanocyte lineagespecific antigen gp100. J Biol Chem. 1994;269(31):20126-20133.
24. Matsui K, Beasley MB, Nelson WK, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol. 2001;25(4):479-484.
25. Matsui K, Takeda K, Yu ZX, et al. Downregulation of estrogen and progesterone receptors in the abnormal smooth muscle cells in pulmonary lymphangioleiomyomatosis following therapy. An immunohistochemical study. Am J Respir Crit Care Med. 2000;161(3):1002-1009.
26. Zhe X, Schuger L. Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis. J Histochem Cytochem. 2004;52(12):1537-1542.
27. Gao L, Yue MM, Davis J, Hyjek E, Schuger L. In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor. Virchows Arch. 2014;464(4):495-503.
28. Matsui K, K Riemenschneider W, Hilbert SL, et al. Hyperplasia of type II pneumocytes in pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2000;124(11):1642-1648.
29. Valencia JC, Pacheco-Rodriguez G, Carmona AK, et al. Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis. Am J Respir Cell Mol Biol. 2006;35(1):40-47.
30. Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol. 2004;28(8):1007-1016.
31. Virador V, Matsunaga N, Matsunaga J, et al. Production of melanocyte-specific antibodies to human melanosomal proteins: expression patterns in normal human skin and in cutaneous pigmented lesions. Pigment Cell Res. 2001;14(4):289-297.
32. Zhang X, Travis WD. Pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2010;134(12):1823-1828.
33. American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144(5):1202-1218.
34. American Thoracic Society. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique - 1995 update. Am J Respir Crit Care Med. 1995;152(6 pt 1):2185-2198.
35. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152(3):1107-1136.
36. Pacheco-Rodriguez G, Steagall WK, Crooks DM, et al. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res. 2007;67(21):10573-10581.
37. van Duinen SG, Ruiter DJ, Scheffer E. A staining procedure for melanin in semithin and ultrathin epoxy sections. Histopathology. 1983;7(1):35-48.
38. Rennison A, Duff C, McPhie JL. Electron microscopic identification of aberrant melanosomes using a combined DOPA/Warthin-Starry technique. J Pathol. 1987;152(4):333-336.
39. Dilling DF, Gilbert ER, Picken MM, Eby JM, Love RB, Le Poole IC. A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options. Am J Respir Cell Mol Biol. 2012;46(1):1-5.
40. Klarquist J, Barfuss A, Kandala S, et al. Melanoma-associated antigen expression in lymphangioleiomyomatosis renders tumor cells susceptible to cytotoxic T cells. Am J Pathol. 2009;175(6):2463-2472.
41. Theos AC, Truschel ST, Raposo G, Marks MS. The silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function. Pigment Cell Res. 2005;18(5):322-336.
42. Raposo G, Tenza D, Murphy DM, Berson JF, Marks MS. Distinct protein sorting and localization to premelanosomes, melanosomes, and lysosomes in pigmented melanocytic cells. J Cell Biol. 2001;152(4):809-824.
43. Raposo G, Marks MS. Melanosomes-dark organelles enlighten endosomal membrane transport. Nat Rev Mol Cell Biol. 2007;8(10):786-797.